We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
The latest trading session saw Vertex Pharmaceuticals (VRTX - Free Report) ending at $503.20, denoting a -1.37% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of 0.08%. At the same time, the Dow added 0.08%, and the tech-heavy Nasdaq gained 0.52%.
Shares of the drugmaker witnessed a gain of 6.21% over the previous month, beating the performance of the Medical sector with its loss of 1.03% and the S&P 500's loss of 7.33%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. In that report, analysts expect Vertex Pharmaceuticals to post earnings of $4.19 per share. This would mark a year-over-year decline of 11.97%. In the meantime, our current consensus estimate forecasts the revenue to be $2.81 billion, indicating a 4.56% growth compared to the corresponding quarter of the prior year.
VRTX's full-year Zacks Consensus Estimates are calling for earnings of $17.65 per share and revenue of $11.85 billion. These results would represent year-over-year changes of +4102.38% and +7.56%, respectively.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Vertex Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.19% higher. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
Digging into valuation, Vertex Pharmaceuticals currently has a Forward P/E ratio of 28.9. This valuation marks a premium compared to its industry's average Forward P/E of 19.05.
We can also see that VRTX currently has a PEG ratio of 1.24. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.56.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading session saw Vertex Pharmaceuticals (VRTX - Free Report) ending at $503.20, denoting a -1.37% adjustment from its last day's close. The stock's change was less than the S&P 500's daily gain of 0.08%. At the same time, the Dow added 0.08%, and the tech-heavy Nasdaq gained 0.52%.
Shares of the drugmaker witnessed a gain of 6.21% over the previous month, beating the performance of the Medical sector with its loss of 1.03% and the S&P 500's loss of 7.33%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. In that report, analysts expect Vertex Pharmaceuticals to post earnings of $4.19 per share. This would mark a year-over-year decline of 11.97%. In the meantime, our current consensus estimate forecasts the revenue to be $2.81 billion, indicating a 4.56% growth compared to the corresponding quarter of the prior year.
VRTX's full-year Zacks Consensus Estimates are calling for earnings of $17.65 per share and revenue of $11.85 billion. These results would represent year-over-year changes of +4102.38% and +7.56%, respectively.
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Vertex Pharmaceuticals. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.19% higher. Vertex Pharmaceuticals currently has a Zacks Rank of #3 (Hold).
Digging into valuation, Vertex Pharmaceuticals currently has a Forward P/E ratio of 28.9. This valuation marks a premium compared to its industry's average Forward P/E of 19.05.
We can also see that VRTX currently has a PEG ratio of 1.24. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. As of the close of trade yesterday, the Medical - Biomedical and Genetics industry held an average PEG ratio of 1.56.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 75, putting it in the top 30% of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.